Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/13/2018 |
| Start Date: | June 2002 |
| End Date: | June 2019 |
| Contact: | Samuel Singer, M.D. |
| Phone: | 212-639-2940 |
The purpose of this study is to study normal and sarcoma cells. To study these cells we need
to have human tissue. You will be having or have already had a procedure to remove tissue. We
would like to use some of this tissue. We will use it for laboratory studies on the
diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your
samples. We will only use extra tissue left over after all needed testing has been done or
remove an additional small amount of tissue if you are having a biopsy. We will also take
blood samples before and/or after your procedure to measure biochemical factors that may help
us predict the behavior of sarcoma.
to have human tissue. You will be having or have already had a procedure to remove tissue. We
would like to use some of this tissue. We will use it for laboratory studies on the
diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your
samples. We will only use extra tissue left over after all needed testing has been done or
remove an additional small amount of tissue if you are having a biopsy. We will also take
blood samples before and/or after your procedure to measure biochemical factors that may help
us predict the behavior of sarcoma.
In this protocol, we plan to identify specific markers from biochemical, proteomic,
epigenetic and molecular genetic analyses that predict clinical outcome, responsiveness to
therapy and might serve as promising therapeutic targets in patients with soft tissue
sarcoma.
epigenetic and molecular genetic analyses that predict clinical outcome, responsiveness to
therapy and might serve as promising therapeutic targets in patients with soft tissue
sarcoma.
Inclusion Criteria:
- All patients with known or suspected sarcoma who will have or have had tissue removed
for therapeutic or diagnostic purposes.
- Patients will be entered without preference for any particular racial/ethnic group or
gender.
- Patients may have received prior hormonal therapy, cytotoxic chemotherapy,
irradiation, immunotherapy or surgical therapy.
- Tissue specimens must be large enough in quantity to allow routine pathologic
analysis, with the research laboratory specimen removed from the residual specimen,
which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core
biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma specimen-
1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue - 0.5 to 4.0
grams (if available from resected sarcoma specimen) Optimal tissue amounts for RNA
later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes)
Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or muscle
tissue - 30 mg (three 3 x 3 x 3 mm cube
Exclusion Criteria:
- None
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Harrison, New York 10604
Phone: 212-639-2940
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Samuel Singer, M.D.
Phone: 212-639-2940
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials